Pałgan Krzysztof, Bartuzi Zbigniew
Department of Allergology, Clinical Immunology and Internal Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University of Toruń, Poland
Department of Allergology, Clinical Immunology and Internal Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University of Toruń, Poland.
Int J Immunopathol Pharmacol. 2015 Sep;28(3):415-20. doi: 10.1177/0394632015580907. Epub 2015 Apr 1.
Bronchial asthma is a chronic inflammatory disease characterised by airflow obstruction that may be reversed spontaneously or in response to treatment. The airway inflammation can lead to structural changes and remodelling consisting of subepithelial layer thickening, airway smooth muscle hyperplasia and angiogenesis. Subepithelial hypervascularity and angiogenesis in the airways are part of the structural airway wall in asthma. Increased vascularity of bronchial mucosa is closely related to the expression of angiogenic factors like vascular endothelial growth factor (VEGF), angiopoietin and hypoxia-inducible factor (HIF). The scope of the present review is to summarise the roles of anagiogenic factors and treatment in vascular development.
支气管哮喘是一种慢性炎症性疾病，其特征为气流阻塞，这种阻塞可能会自发缓解或对治疗产生反应。气道炎症可导致结构改变和重塑，包括上皮下增厚、气道平滑肌增生和血管生成。气道上皮下血管增多和血管生成是哮喘气道壁结构的一部分。支气管黏膜血管增多与血管内皮生长因子（VEGF）、血管生成素和缺氧诱导因子（HIF）等血管生成因子的表达密切相关。本综述的范围是总结血管生成因子和治疗在血管发育中的作用。
